MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Caliper closes Xenogen Biosciences small animal deal, lowers Q4 guidance

Caliper closes Xenogen Biosciences small animal deal, lowers Q4 guidance

By

Caliper Life Sciences Inc. (NSDQ:CALP) closed an $11 million deal to sell Xenogen Biosciences Corp. to Taconic Farms Inc. and lowered its fourth-quarter guidance as a result.

The Hopkinton, Mass.-based lab equipment and services provider acquired XenBio subsidiary, which supplies genetically altered small animals to drug developers, when it bought Xenogen Corp. in 2006. About 90 percent of the business involves selling genetically engineered rodents called “light producing transgenic animals,” which have been modified to produce substances that fluoresce when examined using special imaging equipment, according to Caliper’s website.

Caliper makes the equipment designed to highlight these “optical reporters,” such as luciferase, and the deal includes a distribution agreement between the company and Taconic. The Hudson, N.Y.-based small research animal supplier will distribute the Caliper light-producing transgenic animals and have the non-exclusive right to “perform imaging services under Caliper’s extensive patent estate in this field,” according to a press release. Taconic will also be able to develop new LPTA lines compatible with the Ivis imaging system.

Caliper president and CEO Kevin Hrusovsky said the deal help his company consolidate and focus on one of its core businesses, optical imaging. Caliper will get about $9 million in cash up front during the fourth quarter, plus future payments from the distribution and licensing deal.

The company downgraded its sales forecast for the fourth quarter as a result of the deal, to $33 million to $35 million. Its previous guidance was for Q4 revenues of $34.5 million to $36.5 million.

Caliper narrowed its net loss by more than 37 percent during the third quarter, despite a top-line slide of nearly 6 percent, with revenues of $32.2 million during the three months ended Sept. 30 (compared with $34 million during the same period last year). Net losses for the quarter were $3.4 million, down 37.4 percent compared with $5.4 million during the third quarter of 2008.

In case you missed it

RSS From Medical Design & Outsourcing

  • Medtronic, Johnson & Johnson warn of hospital worker burnout headwind
    Medical device manufacturers are worried that the COVID-19 pandemic’s latest wave will make for a tougher recovery in elective procedures after Delta variant cases subside. Top officials from Medtronic (NYSE:MDT), Johnson & Johnson (NYSE:JNJ), NuVasive (NASDAQ: NUVA) and Zimmer Biomet Holdings (NYSE:ZBH) recently warned investors of the problem. The concern is that the highly contagious… […]
  • Medline inks a strategic partnership with Arnot Health
    Medline announced that it has forged a $40 million prime vendor partnership with New York-based Arnot Health. As the system’s primary supplier, Medline will exclusively provide an extensive portfolio of medical supplies and services to three diverse healthcare campuses across the southern tier of New York, the company said yesterday. The two organizations will identify… […]
  • GE warns of supply chain strain well into 2022
    Medical device makers and suppliers seeking relief from the global semiconductor shortage will have to hold on a while longer. GE (NYSE:GE) is warning investors that supply and labor shortages are squeezing its Healthcare business this quarter and that the pressure won’t likely let up in 2021. GE Healthcare’s business “largely is a supply chain… […]
  • Theranos whistleblower testifies to blood analyzer inaccuracies in Elizabeth Holmes fraud trial
    One of Theranos’ whistleblowers testified on the inaccuracies in the blood analyzers that Theranos had touted to investors on the third day of Elizabeth Holmes’ federal fraud trial. Erika Cheung, a former Theranos lab associate, testified yesterday that the machines the company was using to conduct patient blood tests had inaccuracies of quality control test… […]
  • CMS aborts launch of MCIT payment program for breakthrough devices
    CMS intends to kill the Medicare Coverage of Innovative Technology (MCIT) program that would have accelerated government payments for medical devices designated by the FDA as breakthroughs. CMS (the U.S. Centers for Medicare & Medicaid Services) disclosed its proposal in the Federal Registrar yesterday — three months before the rule was set to take effect… […]
  • One of FDA’s top lawyers leaves to join Greenberg Traurig
    Greenberg Traurig recently announced that James C. Fraser, a former associate chief counsel for litigation at the FDA, has joined its Litigation and Health Care & FDA practices in Washington, D.C. Fraser left FDA in August. He has more than 16 years of experience in life sciences litigation and most recently worked in conjunction with… […]
  • September 2021 Issue: Our latest Medical Device Handbook is out!
      Making medical devices: Everything you need to know The innovation-fueled evolution of drug eluting stents Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’ Getting the inside scoop behind top medtech innovations Autumn is upon us, and it is once again time to sip a pumpkin spice latte  — or a pumpkin beer —… […]
  • Steris launches two new vaporized hydrogen peroxide biodecontamination systems
    Steris has launched the next generation of its vaporized hydrogen peroxide (VHP) biodecontamination systems to achieve 6-log bioburden reduction in good-manufacturing-practice pharmaceutical, medical device and research environments. It’s possible to integrate the new VHP 100i and 1000i systems into a facility’s building automation and HVAC systems, running a decontamination cycle at programmed intervals or at… […]
  • First witnesses in Elizabeth Holmes federal fraud trial take the stand
    Two of the prosecution’s witnesses took the stand yesterday on the second day of Elizabeth Holmes’ federal fraud trial. Theranos’ former financial controller San Ho Spivey, who is referred to as Danise Yam, took the stand and testified about the company’s financial condition during its heyday. Yam told Assistant U.S. Attorney Robert Leach that Theranos… […]
  • Axonics loses IP challenge to Medtronic patents
    Medtronic (NYSE:MDT) announced that it picked up three victories in an intellectual property (IP) dispute against Axonics (NSDQ:AXNX) over sacral neuromodulation devices. According to a news release, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) rejected Axonics’ attempt to invalidate three Medtronic patents in its IP infringement lawsuit related to Medtronic’s InterStim neuromodulation device… […]
  • Cepheid wins EUA for new version of COVID-19, flu, RSV combination diagnostic
    Cepheid announced today that it received FDA emergency use authorization (EUA) for its Xpert Xpress CoV-2/Flu/RSV Plus diagnostic. Sunnyvale, California-based Cepheid designed its Xpert Xpress Plus as a rapid molecular diagnostic test for the qualitative detection of the viruses causing COVID-19, Flu A, Flu B and respiratory syncytial virus (RSV). Get the full story at our… […]

Leave a Reply